The US Commercialization Test: Leonardo DRS, Axon USA, and the Gap Between Demos and Follow-On Orders
Axon Vision has already built a real US access layer: a US subsidiary, a Leonardo DRS partnership, and a first order of roughly $350 thousand. But the disclosed ladder still runs through demos and local presence, not follow-on orders that would prove a working commercialization channel.
The US Is No Longer an Idea, But It Is Still Not a Proven Sales Channel
The main article argued that Axon Vision's first wave of orders still did not prove that its commercialization setup could produce repeatable flow. The US thread is the cleanest place to test that claim, because this is where the company moved beyond generic target-market language. It set up a US entity, signed a structured cooperation agreement with Leonardo DRS, moved the company president into the market, and then received a first order under that framework.
That is already a real commercialization move. But it still does not prove a channel. The reason is straightforward: what has been disclosed so far runs through customer access, joint demonstrations, and local presence-building. It has not yet reached the stage that can fairly be called repeat follow-on orders, or even a US order disclosed as procurement rather than demonstration. That is why the US path is the company's most important thesis test. If this ladder matures, Axon gets more than another customer. It gets a real route into the US defense market. If it does not, then what exists here is strong capability proof with a serious partner, but not yet a proven sales engine.
| Step | What was disclosed | What it does prove | What it still does not prove |
|---|---|---|---|
| April 2025 | Axon Vision Inc. was incorporated in Delaware, wholly owned, to advance sales and marketing in the US, build ties with customers and defense bodies, and develop partnerships; the company says it is still in the stage of first sales and marketing activity | The company is building direct local presence rather than trying to sell only from Israel | A mature local sales setup or a repeatable sales pace |
| November 2025 | A 5-year strategic cooperation agreement was signed with Leonardo DRS | The company has a structured access route into the US market through a large player | A committed follow-on order stream with defined scale |
| January 2026 | A first order of about $350 thousand was received for two prototype systems | The agreement can already produce a concrete order and is not just a framework | A move from demonstration stage into procurement or deployment |
| January 2026 | The company president completed a move to the US, and the company agreed to cover relocation expenses up to NIS 400 thousand annually against receipts | The US push now carries senior-management attention and real cost | That local presence has already translated into a durable order funnel |
What Leonardo DRS Actually Gives Axon
The Leonardo DRS agreement matters not because of the name alone, but because of the structure. For the specific US opportunities defined in the agreement, Leonardo DRS acts as the prime contractor in joint bids, while Axon remains the design authority for its own products inside the system. That is a smart setup. It gives Axon access to frameworks where a large American integrator knows how to speak to an American defense customer, without stripping the company of control over its own technology layer.
The IP line also matters. Each side keeps its own intellectual property rights, and developments derived from Axon's technology remain with Axon. So this is not a case of the company handing over the product in exchange for access. It is an attempt to combine American market access with retained technological control.
There is another important nuance. The cooperation is exclusive only for the joint proposals explicitly defined in the agreement, not outside them. Each side may still offer its products independently beyond that framework. In other words, this is not Axon outsourcing its entire US commercialization effort to Leonardo DRS. It is a focused route for specific opportunities in situational awareness, lethality, and survivability, with emphasis on counter-drone solutions for armored vehicles. The upside is obvious: the company gets a practical shortcut into a market that is extremely hard to penetrate alone. The limitation is equally obvious: even with the agreement in place, it still has to prove one opportunity after another.
That is exactly why the January order should not be overstated. It does not prove Leonardo DRS has already built a US order engine for Axon. It proves something narrower but meaningful: that the partnership has already moved from paper to hardware, software, and joint demonstration activity in front of US defense customers. That is a real stage. It is just not the last one.
The Company Is Already Paying the Entry Cost
The US story is not a cost-free thesis resting on announcements. The company is already building this path through the income statement. In the annual report it says that over the coming year it plans to increase investment in sales and marketing, with emphasis on business development in the US. In the board report it explains that net sales and marketing expense rose to NIS 7.58 million in 2025 from NIS 3.03 million in 2024, partly because of broader employee coverage across territories that enables penetration into Europe and the US, higher spending on agents and advisers, and expenses tied to demonstrations and conferences.
General and administrative expense also rose to NIS 4.51 million from NIS 2.32 million, and the company explicitly links part of that increase to legal and operating costs tied to establishing the US entity. So the US market already appears in the report not only as an opportunity, but as a cost line. That matters, because it raises the standard for how this path should be judged. At this stage it is not enough to hear that there is a local partner and that there are demonstrations. The company needs to show that this spending is starting to build a repeatable funnel.
The January Order Proves Access, Not Conversion
The January 12, 2026 immediate report is the core of this continuation. One day earlier Axon received an order from the customer under the Leonardo DRS cooperation framework for about $350 thousand. The order includes two prototype demonstration systems intended for joint demonstrations to customers among US security forces, and the system is expected to participate in several exercises and showcase events across different platforms.
This is real commercial progress. A young defense technology company that moves within a relatively short time from establishing a US entity, to signing with a major integrator, to receiving a first order aimed at US demonstration events has clearly crossed a line. But the exact line matters. This is still not a series-production order. It is not disclosed as operational procurement. It is an order for two demo prototypes designed to open doors and prove capability.
The annual report itself offers the right lens for reading that stage. In another context, when describing work with the Ministry of Defense, the company says that at the demonstration and feasibility-testing stage there is a risk that the demo does not succeed or that the process does not mature into a binding order. That statement is not made directly about the US thread, so it would be wrong to present it as a US-specific fact. But it is the right reminder for why a first commercial step should not be confused with full commercialization proof. If the product moves from demos to exercises, then to integration, and then to a follow-on order, the channel is being built. If not, the January order remains primarily proof of access.
Axon USA and Ido Rosenberg's Relocation Are a Serious Signal, But Also an Admission of How Hard the Task Is
At the report date Axon USA is still not presented as a subsidiary that is already generating measurable results. It is presented as a platform under construction. The company says explicitly that it is in the stage of first marketing and sales efforts in the US, organizing a local workforce, and building strategic partnerships. That is not the language of a company that has already closed the market-entry loop. It is the language of a company building the pipe now.
That is where Ido Rosenberg's move to the US in January 2026 becomes important. The fact that the company president and CTO physically relocated to the US as part of the group's expansion into the US and Canada and the establishment of the American entity says two things at the same time. On one hand, the company clearly understands that an American commercialization route is not built remotely. It requires a senior person on the ground, with integrators, customers, demo events, and adaptation work. On the other hand, it also reveals the bottleneck: if one of the founders needs to relocate in order to hold the line, the channel is still not institutionalized.
Put differently, the relocation strengthens the thesis only partly. It proves commitment. It does not prove that the commitment has already turned into a system.
What Has to Happen for the Market to Stop Reading This as Mostly Demonstration
The next step Axon needs to prove is easy to define and hard to execute.
First, the company needs to show a follow-on order that is not designed mainly for demonstration events, but is tied to platform integration, operational supply, or a defined procurement route. Without that, the January order remains a positive mid-ladder milestone, not a finished commercialization proof.
Second, Axon USA needs to move beyond the stage of "first sales and marketing efforts" into a phase where its role becomes more measurable in sales, partnerships, or revenue recognition. The current report does not provide that level of detail, which means the funnel is still mostly hidden from outside readers.
Third, the relatively heavy investment in sales and marketing needs to start working economically, not only strategically. In 2025 those expenses rose far faster than revenue. That is not necessarily a negative signal for a defense technology company in a proof year, but it does mean the market will eventually demand more than headline-level language about market penetration.
Bottom Line
Axon Vision's US move has already crossed one threshold. There is a US subsidiary, a large American integrator, a first order, and a senior executive who has relocated into the market to build the route from inside it. So it is no longer accurate to describe the US as a vague commercialization aspiration.
But the reverse is just as important: the path is still not proven as a repeatable order channel. Everything disclosed so far points to the construction of a very good access layer, not to a completed commercial loop. Leonardo DRS solves Axon's problem of getting into the room. It has not yet solved the more important question of what happens after the door opens.
That is why the US remains Axon's real commercialization test. If the next two years turn demonstrations into follow-on orders, turn Axon USA from wrapper into pipe, and turn commercialization spending into backlog and collections, the market will be able to read 2025 as the start of a channel build. If not, the company will have proved technology and market access, but not yet a sales engine.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.